China Insulin Market Review to 2018 - Increasing Focus on R&D Investments

Published: Sep, 2014 | Pages: 80 | Publisher: Ken Research Private Ltd
Industry: Healthcare | Report Format: Electronic (PDF)

Executive Summary
The industry research publication titled ‘China Insulin Market Review to 2018 - Increasing Focus on R&D Investments’ presents a comprehensive analysis of market size by volume and value of major types of insulin consumed in China. The report entails the segment wise market share analysis and company profiles of major players in the insulin market in China. The future analysis of the market has also been discussed in the report.
The prevalence of diabetes in China has grown from 1% per capita in 1980 to more than 12% in 2013, making it the country with the most diabetic cases globally. In addition to 148 million people with pre-diabetes, 98.4 million people were diagnosed with diabetes in the country in 2013. In the near future, 6%-7% of those with pre-diabetes will be added to the existing diabetic population. Additionally, 40% of the youth aged 18-29 are potential diabetes patients with a high risk of stroke, heart disease and renal failure. Thus, the disease has become a matter of grave concern for the country and its wellbeing in the future.
Diabetes has reached catastrophic levels in China. According to the International Diabetes Federation, 98.4 million people in China were diagnosed as diabetic in 2013, representing the country with the largest diabetes cases in the world. The undiagnosed diabetic cases in China amounted to ~ million in 2013. Adding significantly to the mortality rate of China, nearly ~ million people died from diabetes in the country during the same year.
The consumption of insulin, the basis of diabetes care, is gaining momentum in China. With revenue generation of USD ~ million in 2013, China’s insulin market has grown at a tremendous pace since 2008. Although, low awareness relating to diabetes care in the country is a major cause hindering treatment and diagnosis of diabetes, the scenario is witnessing change. With a CAGR of ~% during 2008-2013, the demand for insulin has been underpinned by growing diabetic population, gradually increasing knowledge regarding diabetes care and the rising affluence of the masses. In terms of volume, it is estimated that nearly ~ thousand of million units (tMU) of insulin was consumed in 2013, which has been growing at ~% CAGR from 2008 to 2013.
The insulin market in China is evolving rapidly. Analog insulin has become the preferred choice of the diabetic population in the country not only on account of efficacy, but also the fact that people are being able to afford the high costs that are carried with analog insulin replacement therapy. The market for human insulin in China is being substituted by analog insulin every year. In 2008, the Chinese insulin market was largely composed of human formulations with ~% share, which was reduced to ~% in 2013. The analog insulin market has grown considerably during the same period, registering an impressive CAGR of ~%. In 2013, the value addition to the overall insulin market by the sale of analog insulin was USD ~ million, whereas that of human insulin was USD ~ million.
The government of China is actively involved in resisting the problems related to the increasing prevalence of diabetes in the country. Through the initiation of healthcare reforms, the government has significantly contributed to the growth of the insulin market in China. Medical insurance, drug supply security, medical-service provision and public health services are some of the initiatives undertaken by the government. The government has also collaborated with several leading insulin companies for spreading awareness via campaigns and free diagnostic services.
The rising epidemic of diabetes in China and its economic wellbeing has attracted the major insulin enterprises operating globally. Companies such as Novo Nordisk, Eli Lilly and Sanofi Aventis capture a large proportion of the market, whereas domestic players including Tonghua Dongbao and Shanghai Fosun Pharmaceutical share a small fraction of the Chinese insulin market. Since analog insulin is emerging as the favored choice amongst the diabetic patients in the country, the vast and superior portfolio offered by the foreign multinationals has assisted them in constricting the market. These companies are also carrying out extensive R&D within the country in order to understand the local trends and supplying corresponding solutions.

Key Topics Covered in the Report:
- The market size of China insulin market in terms of value and volume
- Market segmentation by insulin replacement therapy and types of insulin
- Government regulation and support schemes for China’s insulin market
- Trends and developments in China insulin market
- Growth drivers of China insulin market
- Market share of major players in the insulin market in China
- Market share of major players by types of insulin
- Company profiles of major players in China’s insulin market
- Future outlook and projections of the insulin market in China
- Macroeconomic factors affecting the insulin market in China

 Table of Contents
1.	Asia Pacific Insulin Market Introduction
1.1.	Asia Pacific Insulin Market Value Chain
1.2.	Asia Pacific Insulin Market Size by Value, 2008-2013
1.3.	Asia Pacific Insulin Market Segmentation, 2008-2013
1.3.1.	By Geography, 2008-2013
1.3.2.	By Insulin Replacement Therapy (Human Insulin and Analog Insulin), 2013
1.3.3.	By Types of Insulin (Premix, Rapid Acting, Long Acting), 2013
1.4.	New Product Development By Major Insulin Companies
1.5.	Trends and Developments in Asia Pacific Insulin Market
Monopoly of Foreign Brands
Phasing Out of Human Insulin
1.6.	Growth Drivers and Challenges in Asia Pacific Insulin Market
Shift from Human Insulin to Analog Insulin
Rising Prevalence of Diabetes
Increasing Diabetes Care Expenditure
Low Affordability
Lack of Awareness
1.7.	SWOT Analysis of Asia Insulin Market
1.8.	Asia Pacific Insulin Market Future Outlook and Projections, 2014-2018
1.8.1.	By Geography, 2014-2018

2.	China Insulin Market Introduction

3.	China Insulin Market Size by Sales Value and Volume, 2008-2013

4.	China Insulin Market Segmentation, 2008-2013
4.1.	By Insulin Replacement Therapy (Human Insulin and Analog Insulin), 2008-2013
4.2.	By Types of Insulin (Premix, Long Acting, Rapid Acting) 
4.2.1.	By Consumption Volume, 2008-2013
4.2.2.	By Revenue, 2008-2013
4.2.3.	Usage by Type of Diabetes, 2013

5.	Government Regulations and Support Schemes for China Insulin Market
Drug Licensing Process
China National Plan for Chronic Disease Prevention and Treatment (2012-15) 
Healthcare Reforms in China

6.	Trends and Developments in China Insulin Market
Increasing Investment by Multinational Companies
Patent Expiry for Major Insulin Brands in China

7.	Growth Drivers in China Insulin Market
Aging Population in China
Government Support for the Insulin Market in China

8.	Market Shares of Major Companies in China Insulin Market
8.1.	By Revenue, 2013
8.2.	By Volume, 2010-2013
8.3.	By Insulin Replacement Therapy (Human Insulin and Analog Insulin), 2013
8.3.1.	By Human Insulin, 2010 and 2013
8.3.2.	By Analog Insulin, 2013
8.4.	By Type of Insulin, 2013
8.4.1.	By Premix Insulin, 2013
8.4.2.	By Long Acting Insulin, 2013
8.4.3.	By Rapid Acting Insulin, 2013

9.	Company Profiles of major Players in China Insulin Market
9.1.	Novo Nordisk (China) Pharmaceutical Co. Ltd. 
9.1.1.	Company Overview
9.1.2.	Business Strategies
Increasing Diabetes Care Awareness
Strengthening Manufacturing and R&D Activities
9.1.3.	Competitive Standing
9.2.	Eli Lilly and Company
9.2.1.	Company Overview
9.2.2.	Business Strategies
Expanding Supply Chain and Distribution Through Local Distribution Partners
9.2.3.	Competitive Standing
9.3.	Sanofi China
9.3.1.	Company Overview
9.3.2.	Competitive Standing
9.4.	Other Companies in China Insulin Market
9.4.1.	BJ Ganli Pharmaceuticals
Company Overview
Competitive Standing
9.4.2.	Tonghua Dongbao Pharmaceutical Co. Ltd. 
Company Overview
Competitive Standing

10.	China Insulin Market Future Outlook and Projections, 2014-2018
10.1.	By Insulin Replacement Therapy, 2014-2018
10.2.	By Type of Insulin, 2014-2018
10.3.	Cause and Effect Relationship Between Dependable and Independent Variable Factors prevailing in India Insulin Market

11.	Macroeconomic Factors in China Insulin Market, 2008-2018
11.1.	Diabetic Population in China, 2008-2018
11.2.	China Government Spending on Healthcare, 2008-2018
11.3.	China Per Capita Expenditure on Healthcare, 2008-2018
11.4.	China Personal Disposable Income, 2008-2018

12.	Appendix
12.1.	Market Definitions
12.2.	Abbreviations
12.3.	Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent) 
Final Conclusion
12.4.	Disclaimer

List of Tables
Table 1: Top 10 Countries with the Largest Diabetic Population Globally, 2013
Table 2: Asia Pacific Insulin Market Segmentation on the Basis of Revenue of Different Geographies in USD Million, 2008-2013
Table 3: Asia Pacific Insulin Market Segmentation by Insulin Replacement Therapy (Human Insulin and Analog Insulin) on the Basis of Revenue in USD Million, 2013
Table 4: Asia Insulin Market Segmentation by Types of Insulin (Premix, Rapid Acting and Long Acting) on the Basis of Revenue in USD Million, 2013
Table 5: New Insulin Development by Major Insulin Companies
Table 6: Mean Diabetes Related Expenditure Per Person with Diabetes in USD, 2012-2013
Table 7: SWOT Analysis of Asia Insulin Market
Table 8: Asia Pacific Insulin Market Future Projection by Geography on the Basis of Revenue in USD Million, 2014-2018
Table 9: China Insulin Market Segmentation by Insulin Replacement Therapy (Human Insulin and Analog Insulin) on the Basis of Revenue in USD Million, 2008-2013
Table 10: China Insulin Market Segmentation by Type of Insulin (Premix, Long Acting and Rapid Acting) on the Basis of Consumption Volume in Thousand of Million Units (tMU), 2008-2013
Table 11: China Insulin Market Segmentation by Types of Insulin (Premix, Long Acting and Rapid Acting) on the Basis of Revenue in USD Million, 2008-2013
Table 12: China Insulin Market Segmentation by Type 1 and Type 2 Diabetes on the Basis of Revenue in USD Million, 2013
Table 13: Patent Expiry for Major Insulin Brands in China
Table 14: Revenue of Major Companies in China Insulin Market in USD Million, 2013
Table 15: Market Share of Major Companies in China Insulin Market on the Basis of Volume in tMU, 2010-2013
Table 16: Revenue of Major Companies in China Human Insulin Market in USD Million, 2010 and 2013
Table 17: Revenue of Major Companies in China Analog Insulin Market in USD Million, 2010 and 2013
Table 18: Brand-wise Revenue of Major Companies in China Premix Insulin Market in USD Million, 2013
Table 19: Brand-wise Revenue of Major Long Acting Insulin Brands in China in USD Million, 2013
Table 20: Brand-wise Revenue of Major Rapid Acting Insulin Brands in China in USD Million, 2013
Table 21: Lantus Sales in China in USD Million, 2009-2013
Table 22: China Insulin Market Future Projections on the Basis of Revenue by Insulin Replacement Therapy in USD Million, 2014-2018
Table 23: China Insulin Market Future Projections on the Basis of Revenue by Insulin Type of Insulin in USD Million, 2014-2018
Table 24: Cause and Effect Relationship between the Dependent and Independent Variables Prevailing in India Insulin Market
Table 25: Correlation Matrix of India Insulin Market
Table 26: Regression Coefficients Output